EHA 2024 | An insight into the knowledge gaps in cardio-oncology when treating CLL with BTKi-based therapies
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute, Charlotte, NC, discusses some of the remaining knowledge gaps in cardio-oncology for chronic lymphocytic leukemia (CLL), focusing on BTK inhibitor (BTKi)-based therapies. BTKis are a mainstay of treatment in CLL, and while second-generation BTKis have a more favorable cardiac toxicity profile than ibrutinib, the risk of atrial fibrillation and ventricular events remains. It is, therefore, necessary to standardize cardiac risk assessment of patients to identify which individuals may benefit from BCL2 inhibition to reduce their likelihood of cardiac events. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
